2. Tan L, Zhang Z, Gao D, Chan S, Luo J, Tu Z, Zhang Z, Ding K, Ren X*, Lu X*. Quinolone antibiotic derivatives as new selective Axl kinase inhibitors. Eur J Med Chem. 2019, 166:318-327.（共同通讯作者）

3. Tan L, Zhang Z, Gao D, Luo J, Tu ZC, Li Z, Peng L, Ren X*, Ding K*. 4- Oxo-1,4 – dihydroquinoline -3 -carboxamide Derivatives as New Axl Kinase Inhibitors.  J Med Chem. 2016;59(14).（共同通讯作者）

4. Mo C, Zhang Z, Guise CP, Li X, Luo J, Tu Z, Xu Y, Patterson AV, Smaill JB, Ren X*, Lu X*, Ding K*. 2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors. ACS Med Chem Lett. 2017，31;8(5):3-548. （共同通讯作者）

5. Li Y, Cheng H, Zhang Z, Zhuang X, Luo J, Long H, Zhou Y,  Taghipouran R, Li D, Patterson A. Smail,  Tu Z, Wu, D, Ren X*, Ding K*. N- - (3 – Ethynyl -2, 4- difluorophenyl ) sulfonamide Derivatives as Selective Raf Inhibitors. ACS Med. Chem. Lett. 2015, DOI: 10.1021/ acsmedchemlett. 5b00039（共同通讯作者）

6. Li Y, Lu X,Ren X*, Ding K* Small Molecule Discoidin Domain Receptor Kinase Inhibitors and Potential Medical Applications. J. Med. Chem. 2015, DOI: 10.1021/jm5012319. （共同通讯作者）

7. Ren X, Pan X, Zhang Z, Wang D, Lu X, Li Y, Wen D, Long H, Luo J, Feng Y, Zhuang X, Zhang F, Liu J, Leng F, Lang X, Bai Y, She M, Tu Z, Pan J, Ding K*. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and non-phosphorylated Bcr-Abl and overcomes clinically acquired mutation-induced resistance against imatinib. J. Med. Chem. 2013, 56(3), 879-894. (共同第一作者)

8. She Y, Ren X, Ding K, Zhang Z, Wang D, Pan J*. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells. Oncotarget 2014, 5(21):10407-10420. (共同第一作者)

9. Xu S, Zhuang X, Pan X, Zhang Z, Duang L, Liu Y, Zhang L, Ren X*; Ding K*. 1-Phenyl-4-benzoyl-1H-1,2,3-triazoles as Orally Bioavailable Transcriptional Function Suppressors of Estrogen-Related Receptor α. J. Med. Chem. 2013, 56, 4631？4640. （共同通讯作者 ）

10. Ren X, He Q, Duan L, Zhang Z, Zhou Y, Wu D, Pan J, Ding K*. Identification of a New Small-Molecule Inhibitor of STAT3 Signaling Pathway by Using a “Repositioning” Strategy. ACS Med. Chem. Lett. 2010, 1 (9), 454–459. (第一作者)

11. Peng L, Zhang Z, Lei C, Li S, Zhang Z, Ren X, Chang Y, Zhang Y, Xu Y, Ding K. Identification of New Small-Molecule Inducers of Estrogen-related Receptor α (ERRα) Degradation. ACS Med Chem Lett. 2019;10(5):767-772.

12. Wang Z, Zhang Y, Pinkas DM, Fox AE, Luo J, Huang H, Cui S, Xiang Q, Xu T, Xun Q, Zhu D, Tu Z, Ren X, Brekken RA, Bullock AN, Liang G, Ding K, Lu X. Design, Synthesis, and Biological Evaluation of 3- (Imidazo[1,2-a] pyrazin-3-ylethynyl) -4 -isopropyl-N-(3- ((4-methylpiperazin-1-yl) methyl) -5- (trifluoromethyl) phenyl) benzamide as a dual Inhibitor of Discoidin Domain Receptors 1 and 2. J Med Chem. 2018 ;61(17):7977-7990.

13. Lu X, Zhang Z, Ren X, Wang D, Ding K. Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl(T315I) inhibitor overcoming acquired imatinib resistance. J Enzyme Inhib Med Chem 2017;32(1):331-336..

14. Zhang Z, Zou J, Yu L, Luo J, Li Y, Tu Z, Ren X, Wei H, Song L, Lu X, Ding K.. YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR(L858R, T790M) -mutant resistance in vitro and in vivo. Cancer Med. 2018;7(4):1430-1439.

15. Aguilera KY, Huang H, Du W, Hagopian MM, Wang Z, Hinz S, Hwang TH, Wang H,Fleming JB, Castrillon DH, Ren X, Ding K, Brekken RA.Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther. 2017 Nov;16(11):2473-2485.

16. Li X, Guise CP, Taghipouran R, Yosaatmadja Y, Ashoorzadeh A, Paik WK, Squire CJ, Jiang S, Luo J, Xu Y, Tu ZC, Lu X, Ren X, Patterson AV, Smaill JB, Ding K.2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. Eur J Med Chem. 2017;135:531-543

17. Chang X, Zhen X, Liu J, Ren X, Hu Z, Zhou Z, Zhu F, Ding K, Nie J. The antihelmenthic phosphate niclosamide impedes renal fibrosis by inhibiting homeodomain-interacting protein kinase 2 expression. Kidney Int. 2017;92(3):612-624.

18.Wang Z, Bian H, Bartual SG, Du W, Luo J, Zhao H, Zhang S, Mo C, Zhou Y, Xu Y, Tu Z, Ren X, Lu X, Brekken RA, Yao L, Bullock AN, Su J, Ding K. Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. J Med Chem.2016;59(12):5911-6.

19. Ambrogio C, Gómez-López G, Falcone M, Vidal A, Nadal E, Crosetto N, Blasco RB, Fernández-Marcos PJ, Sánchez-Céspedes M, Ren X, Wang Z, Ding K, Hidalgo M, Serrano M, Villanueva A, Santamaría D, Barbacid M. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. Nat Med. 2016 ;22(3):270-7.